“Parkinson’s Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.
The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Parkinson’s Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years.
Parkinson’s Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson’s Disease treatment
Emerging Parkinson’s Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.
In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.
In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.
In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.
In December 2024, Belgian pharmaceutical company UCB decided to discontinue the development of minzasolmin for Parkinson’s disease after the ORCHESTRA study did not achieve its primary or secondary endpoints. In the ORCHESTRA proof-of-concept trial (NCT04658186), minzasolmin—an investigational oral small-molecule inhibitor targeting alpha-synuclein misfolding—failed to show superiority over placebo.
In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson’s Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research’s network, will be a site for PhotoPharmics’ LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson’s symptoms.
In September 2024, AbbVie’s recently acquired Parkinson’s disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
Parkinson’s Disease Overview
Parkinson’s disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson’s disease experience difficulties with movement control.
Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights
Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:
KM-819: FAScinate Therapeutics
Prasinezumab: Hoffmann-La Roche
P2B001: Pharma Two B Ltd.
NPT1220-478: Neuropore Therapies, Inc.
Dapansutrile: Olatec Therapeutics
UCB7853: UCB Biopharma
UB-312: Vaxxinity
Emrusolmin: Modag
PT320: Peptron
KDT-3594: Kissei Pharmaceutical
Tavapadon: Cerevel Therapeutics
Parkinson’s Disease Route of Administration
Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Parkinson’s Disease Molecule Type
Parkinson’s Disease Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Parkinson’s Disease Pipeline Therapeutics Assessment
Parkinson’s Disease Assessment by Product Type
Parkinson’s Disease By Stage and Product Type
Parkinson’s Disease Assessment by Route of Administration
Parkinson’s Disease By Stage and Route of Administration
Parkinson’s Disease Assessment by Molecule Type
Parkinson’s Disease by Stage and Molecule Type
DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies
Some of the key companies in the Parkinson’s Disease Therapeutics Market include:
Key companies developing therapies for Parkinson’s Disease are – Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.
Parkinson’s Disease Pipeline Analysis:
The Parkinson’s Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies
Parkinson’s Disease Pipeline Market Drivers
Increasing prevalence of Parkinson’s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson’s Disease Market.
Parkinson’s Disease Pipeline Market Barriers
However, lack of awareness and delayed diagnosis, side effects associated with Parkinson’s disease treatment drugs and other factors are creating obstacles in the Parkinson’s Disease Market growth.
Scope of Parkinson’s Disease Pipeline Drug Insight
Coverage: Global
Key Parkinson’s Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others
Key Parkinson’s Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies
Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers
Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials
Table of Contents
1. Parkinson’s Disease Report Introduction
2. Parkinson’s Disease Executive Summary
3. Parkinson’s Disease Overview
4. Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment
5. Parkinson’s Disease Pipeline Therapeutics
6. Parkinson’s Disease Late Stage Products (Phase II/III)
7. Parkinson’s Disease Mid Stage Products (Phase II)
8. Parkinson’s Disease Early Stage Products (Phase I)
9. Parkinson’s Disease Preclinical Stage Products
10. Parkinson’s Disease Therapeutics Assessment
11. Parkinson’s Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Parkinson’s Disease Key Companies
14. Parkinson’s Disease Key Products
15. Parkinson’s Disease Unmet Needs
16 . Parkinson’s Disease Market Drivers and Barriers
17. Parkinson’s Disease Future Perspectives and Conclusion
18. Parkinson’s Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
